Top Key Companies for Measurable Residual Disease Testing Market: Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health, ICON plc, Invivoscribe, Laboratory Corporation of America Holdings, Mission Bio, Natera, Inc., NeoGenomics Laboratories, Opko Health, Quest Diagnostics Incorporated, Sysmex Corporation, Genetron Health.
Global Measurable Residual Disease Testing Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Measurable Residual Disease Testing Market Overview And Scope:
The Global Measurable Residual Disease Testing Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Measurable Residual Disease Testing utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Global Measurable Residual Disease Testing Market Segmentation
By Type, Measurable Residual Disease Testing market has been segmented into:
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
By Application, Measurable Residual Disease Testing market has been segmented into:
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Regional Analysis of Measurable Residual Disease Testing Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Measurable Residual Disease Testing Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Measurable Residual Disease Testing market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Measurable Residual Disease Testing market.
Top Key Companies Covered in Measurable Residual Disease Testing market are:
Adaptive Biotechnologies Corporation
ArcherDX
Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera
Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Key Questions answered in the Measurable Residual Disease Testing Market Report:
1. What is the expected Measurable Residual Disease Testing Market size during the forecast period, 2026-2035?
2. Which region is the largest market for the Measurable Residual Disease Testing Market?
3. What is the expected future scenario and the revenue generated by different regions and countries in the Measurable Residual Disease Testing Market, such as North America, Europe, AsiaPacific & Japan, China, U.K., South America, and Middle East and Africa?
4. What is the competitive strength of the key players in the Measurable Residual Disease Testing Market on the basis of the analysis of their recent developments, product offerings, and regional presence?
5. Where do the key Measurable Residual Disease Testing companies lie in their competitive benchmarking compared to the factors of market coverage and market potential?
6. How are the adoption scenario, related opportunities, and challenges impacting the Measurable Residual Disease Testing Markets?
7. How is the funding and investment landscape in the Measurable Residual Disease Testing Market?
8. Which are the leading consortiums and associations in the Measurable Residual Disease Testing Market, and what is their role in the market?
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Measurable Residual Disease Testing Market by Type
5.1 Measurable Residual Disease Testing Market Overview Snapshot and Growth Engine
5.2 Measurable Residual Disease Testing Market Overview
5.3 Flow Cytometry
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Flow Cytometry: Geographic Segmentation
5.4 Polymerase Chain Reaction (PCR)
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Polymerase Chain Reaction (PCR): Geographic Segmentation
5.5 Next-Generation Sequencing (NGS)
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Next-Generation Sequencing (NGS): Geographic Segmentation
5.6 Other
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Other: Geographic Segmentation
Chapter 6: Measurable Residual Disease Testing Market by Application
6.1 Measurable Residual Disease Testing Market Overview Snapshot and Growth Engine
6.2 Measurable Residual Disease Testing Market Overview
6.3 Hematological Malignancies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hematological Malignancies: Geographic Segmentation
6.4 Leukemia
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Leukemia: Geographic Segmentation
6.5 Lymphoma
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Lymphoma: Geographic Segmentation
6.6 Solid Tumors
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2026-2035F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Solid Tumors: Geographic Segmentation
6.7 Other
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2026-2035F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Measurable Residual Disease Testing Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Measurable Residual Disease Testing Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Measurable Residual Disease Testing Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ADAPTIVE BIOTECHNOLOGIES CORPORATION
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 ARCHERDX
7.4 INC. (INVITAE CORPORATION)
7.5 ASURAGEN
7.6 ARUP LABORATORIES
7.7 BIO-RAD LABORATORIES
7.8 CERGENTIS B.V.
7.9 F. HOFFMANN- LA ROCHE LTD
7.10 GUARDANT HEALTH
7.11 ICON PLC
7.12 INVIVOSCRIBE
7.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
7.14 MISSION BIO
7.15 NATERA
7.16 INC.
7.17 NEOGENOMICS LABORATORIES
7.18 OPKO HEALTH
7.19 QUEST DIAGNOSTICS INCORPORATED
7.20 SYSMEX CORPORATION
7.21 GENETRON HEALTH
Chapter 8: Global Measurable Residual Disease Testing Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Flow Cytometry
8.2.2 Polymerase Chain Reaction (PCR)
8.2.3 Next-Generation Sequencing (NGS)
8.2.4 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hematological Malignancies
8.3.2 Leukemia
8.3.3 Lymphoma
8.3.4 Solid Tumors
8.3.5 Other
Chapter 9: North America Measurable Residual Disease Testing Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Flow Cytometry
9.4.2 Polymerase Chain Reaction (PCR)
9.4.3 Next-Generation Sequencing (NGS)
9.4.4 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hematological Malignancies
9.5.2 Leukemia
9.5.3 Lymphoma
9.5.4 Solid Tumors
9.5.5 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Measurable Residual Disease Testing Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Flow Cytometry
10.4.2 Polymerase Chain Reaction (PCR)
10.4.3 Next-Generation Sequencing (NGS)
10.4.4 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hematological Malignancies
10.5.2 Leukemia
10.5.3 Lymphoma
10.5.4 Solid Tumors
10.5.5 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Measurable Residual Disease Testing Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Flow Cytometry
11.4.2 Polymerase Chain Reaction (PCR)
11.4.3 Next-Generation Sequencing (NGS)
11.4.4 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hematological Malignancies
11.5.2 Leukemia
11.5.3 Lymphoma
11.5.4 Solid Tumors
11.5.5 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Measurable Residual Disease Testing Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Flow Cytometry
12.4.2 Polymerase Chain Reaction (PCR)
12.4.3 Next-Generation Sequencing (NGS)
12.4.4 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hematological Malignancies
12.5.2 Leukemia
12.5.3 Lymphoma
12.5.4 Solid Tumors
12.5.5 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Measurable Residual Disease Testing Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Flow Cytometry
13.4.2 Polymerase Chain Reaction (PCR)
13.4.3 Next-Generation Sequencing (NGS)
13.4.4 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hematological Malignancies
13.5.2 Leukemia
13.5.3 Lymphoma
13.5.4 Solid Tumors
13.5.5 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Measurable Residual Disease Testing Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Flow Cytometry
14.4.2 Polymerase Chain Reaction (PCR)
14.4.3 Next-Generation Sequencing (NGS)
14.4.4 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hematological Malignancies
14.5.2 Leukemia
14.5.3 Lymphoma
14.5.4 Solid Tumors
14.5.5 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Measurable Residual Disease Testing Scope:
|
Report Data
|
Measurable Residual Disease Testing Market
|
|
Measurable Residual Disease Testing Market Size in 2025
|
USD XX million
|
|
Measurable Residual Disease Testing CAGR 2025 - 2032
|
XX%
|
|
Measurable Residual Disease Testing Base Year
|
2024
|
|
Measurable Residual Disease Testing Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health, ICON plc, Invivoscribe, Laboratory Corporation of America Holdings, Mission Bio, Natera, Inc., NeoGenomics Laboratories, Opko Health, Quest Diagnostics Incorporated, Sysmex Corporation, Genetron Health.
|
|
Key Segments
|
By Type
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
By Applications
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
|
